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ABSTRACT 
Circadian clocks control cellular proliferation and drug metabolism over the 24 h. However, circadian 
chronomodulated chemotherapy with 5-fluorouracil, leucovorin, and oxaliplatin (chronoFLO4) offered no 
survival benefit as compared with the non–time-stipulated FOLFOX2, in an international randomized trial 
involving patients with previously untreated metastatic colorectal cancer (EORTC 05963). The authors 
hypothesized that treatment near maximum tolerated dose could disrupt circadian clocks thus impairing 
the efficacy of chronoFLO4 but not of FOLFOX2. Patients with available data (N = 556) were categorized into 
three subgroups according to the worst grade (G) of neutropenia experienced during treatment. Distinct 
multivariate models with time-dependent covariates were constructed for each treatment schedule. 
Neutropenia incidence (all grades) was 33% on chronoFLO4 and 61% on FOLFOX2 (p < .0001), and G3–4 
were 7% and 25%, respectively (p < .0001). Neutropenia was significantly more frequent in women than 
men on either schedule (FOLFOX2, p = .003; chronoFLO4, p = .04). Median survival was 20.7 mo in patients 
with G3–4 neutropenia versus 12.5 mo in neutropenia-free patients on FOLFOX2 (p < .0001). Corresponding 
figures were 13.7 and 19.4 mo, respectively, on chronoFLO4 (p = .36). Multivariate analysis confirmed 
occurrence of severe neutropenia independently predicted for better overall survival on FOLFOX2 
(HR = 0.56; p = .015), and worse survival on chronoFLO4 (HR = 1.77, p = .06), with a significant interaction 
test (p < .0001). Prediction of better survival in neutropenic patients on FOLFOX2 supports the 
administration of conventional chemotherapy near maximum tolerated dose. The opposite trend shown 
here for chronoFLO4 supports the novel concept of jointly optimized hematologic tolerability and efficacy 
through personalized circadian-timed therapy. (Author correspondence: francis.levi@inserm.fr) 
 




Given the documented large interpatient variability in the catabolic and detoxification rates of anticancer 
drugs (Yang et al., 2010), cytotoxic chemotherapy-induced neutropenia has been advocated as a biological 
indicator of proper dose intensity in individual patients (Felici et al., 2002; Kvinnsland, 1999). Indeed, the 
vast majority of studies has reported survival of neutropenic cancer patients was significantly longer than 
that of patients without such hematologic toxicity, as recently summarized in a meta-analysis (Shitara et al., 
2010a). This was also the case for FOLFOX4 or mFOLFOX6 in an Asian cohort of 153 chemo-naïve patients 
with metastatic colorectal cancer, where neutropenia was positively associated with overall survival, 
independently of all other known prognostic factors (Shitara et al., 2009). In none of these studies was 
chemotherapy timing stipulated (Innominato et al., 2010; Lévi et al., 2010; Shitara et al., 2010a). 
However, circadian timing was shown to significantly modify the extent of toxicity and efficacy of 
anticancer drugs, both in experimental models and cancer patients (Granda & Lévi, 2002; Innominato et al., 
2010; Lévi & Schibler, 2007; Lévi et al., 2010). Indeed, the ∼3-fold order of magnitude of intrapatient 
circadian variability in 5-fluorouracil catabolism by dihydropyrimidine dehydrogenase matched that of 
interpatient variability of the same drug (Gamelin et al., 2008; Harris et al., 1990). Moreover, synchronous 
24-h patterns have been shown for both tolerability and efficacy of most anticancer agents, including 5-
fluorouracil and oxaliplatin (Granda et al., 2002; Peters et al., 1987). As a result, the administration of 
chemotherapy outside the optimal timing window can result both in excessive toxicity and poor antitumor 
efficacy (Lévi et al., 2010). 
The joint optimization of tolerability and efficacy through proper circadian timing of anticancer drugs is 
further supported by proliferation data in human bone marrow and tumor tissue (Abrahamsen et al., 1997; 
Smaaland et al., 1991, 1992b, 1993, 2002). This concept challenges the current oncology principle that 
optimal antitumor effects result from treatment near maximum tolerated dose (Frei & Canellos, 1980). 
Indeed, experimental evidence has now documented that wrongly timed and/or too highly dosed 
anticancer drugs disrupt circadian physiology and/or the molecular clocks that constitute the circadian 
timing system (Lévi et al., 2010). This hierarchical network generates ∼24-h (circadian) oscillations in 
cellular proliferation and metabolism (Lévi et al., 2007a, 2010; Lévi & Schibler, 2007; Liu et al., 2007; Sahar 
& Sassone-Corsi, 2009; Takahashi et al., 2008). Its disruption impairs the physiologic and molecular bases of 
treatment delivery according to circadian rhythms, so-called chronotherapy (Lévi et al., 2010). 
In the current study, we investigated whether the relevance of chemotherapy-induced neutropenia for 
overall survival prediction also applied to patients treated with chronotherapy. Thus, in clinical oncology, 
toxicity of cancer chemotherapy is often positively associated with its efficacy (Frei & Canellos, 1980; 
Shitara et al., 2010a). This observation has given rise to the general oncologic practice of trying to treat 
each patient with therapy intensity titrated to near that individual's maximum tolerated dose. Generally 
positive results of this approach have led oncologists to the acceptance of the opinion that, in order to be 
effective, some level of cytotoxic drug toxicity must be accepted. However, chronotherapy work on both 
sides of the Atlantic done over several decades has repeatedly and convincingly shown that when cytotoxic 
drugs are administered at their optimum times of day in order to avoid or minimize drug toxicity, this 
expected relationship between toxicity and efficacy is altered. In particular, higher doses can often be given 
with lower toxicity and concomitant increased or equal efficacy (Hrushesky, 1985; Lévi et al., 1990, 1997). 
The large randomized controlled multicenter clinical trial analyzed here confirms this dissociation as a 
unique reality in clinical oncology (Giacchetti et al., 2006). Herein, specifically, we first attempt to validate 
the positive association between neutropenia and survival in an independent cohort of patients receiving 
non–time-stipulated chemotherapy, with intrapatient dose escalation up to maximum tolerated dose. The 
hypothesis that chronotherapy achieves best efficacy if tolerability is good is explored here clinically, using 
a data set obtained in a multicenter, randomized, controlled, phase III trial. The study compared 
chronomodulated (chronoFLO4) versus conventional (FOLFOX2) flat infusion schedules combining 
oxaliplatin (l-OHP), 5-fluorouracil (5-FU), and leucovorin (LV), as first-line treatment for patients with 
metastatic colorectal cancer (EORTC 05963) (Giacchetti et al., 2006). Thus, in this trial, the patients received 
the same starting doses of the same drugs at the same frequency, though with pharmacologically different 
delivery schedules (Figure 1). 
 
 
FIGURE 1. Chemotherapy delivery schedules. Top panel: conventional 2-day schedule FOLFOX2, with no 
stipulation of drug-administration time. Bottom panel: chronomodulated 4-day schedule chronoFLO4, with 
defined drug-administration time. Each schedule associated oxaliplatin (white), 5-fluorouracil (light gray), 
and leucovorin (dark gray) infusions were given fortnightly. 5-Fluorouracil dose was increased up to 20% if 
no Grade ≥2 toxicity occurred. 
 
  
MATERIALS AND METHODS 
 
Study Population  
This study describes the results of an unplanned analysis of prospectively collected data from the 
international EORTC 05963 phase III trial, in previously untreated patients with metastatic colorectal 
cancer, randomized to receive either a conventional flat FOLFOX2 or a chronomodulated chronoFLO4 
schedule (Giacchetti et al., 2006). From October 1998 to February 2002, this trial enrolled 564 patients 
from 36 institutions in 10 countries (Giacchetti et al., 2006). The study, conducted in accordance with the 
Helsinki Declaration, was approved by the respective national ethics review boards involved, and all 
patients provided a signed informed consent (Portaluppi et al., 2010). Admission criteria in this trial 
included histologically proven, previously untreated colorectal adenocarcinoma with measurable and 
surgically unresectable metastatic lesions outside the brain, written informed consent according to national 
laws, adequate hematologic, renal, and hepatic functions, performance status (PS)  ≤ 2 (World Health 
Organization [WHO] scale), age between 18 and 76 yrs, and no concomitant other cancer nor overt and 
uncontrolled cardiac, respiratory, chronic, or infectious diseases (Giacchetti et al., 2006). 
 
Chemotherapy Schedules  
FOLFOX2 involved the administration of l-OHP and LV as 2-h flat (non-varying-in-time constant) infusions on 
day 1, followed by constant-rate infusional 5-FU for 22 h. LV was administered again on day 2 after 5-FU, 
and it was followed by constant-rate 5-FU infusion for 22 h (de Gramont et al., 1997; Giacchetti et al., 2006) 
(Figure 1, top panel). 
ChronoFLO4 consisted of a 4-day course of alternating chronomodulated infusions of 5-FU–LV from 22:15 
to 09:45 h, with a peak flow rate at 04:00 h, and l-OHP from 10:15 to 21:45 h, with a peak flow rate at 
16:00 h (Giacchetti et al., 2006; Lévi et al., 1999) (Figure 1, bottom panel). 
Courses were repeated in both arms every 14 days. Drug starting doses, 5-FU dose-escalation scheme, and 
drug-dose reductions followed the same guidelines in both arms. The starting doses per course were 
100 mg/m2 for l-OHP, 1200 mg/m2 for LV, and 3000 mg/m2 for 5-FU. This latter dose could be increased by 
400 mg/m2 on the second and by an additional 200 mg/m2 on the third course, if no Grade ≥2 toxicity 
occurred. Dose reductions (200 and 400 mg/m2/course for 5-FU and 10 and 20 mg/m2/course for l-OHP for 
Grades 3 and 4, respectively) were planned for patients experiencing clinical (diarrhea, stomatitis, hand-
foot syndrome) and/or hematological (neutropenia, thrombocytopenia) toxicities. The subsequent course 
was delayed until every toxic event recovered to Grade 0 or 1 (National Cancer Institute Common Toxicity 
Criteria, version 2) (Giacchetti et al., 2006). Delivered dose intensities for l-OHP and 5-FU were calculated 
during the whole treatment duration as the actual total dose administered/m2/wk between day 1 of the 
first course until day 14 of the last course of chemotherapy received. 
 
Neutropenia Evaluation  
A complete hematologic assessment was performed fortnightly, prior to each chemotherapy 
administration. Neutropenia was graded after each course according to the Common Terminology Criteria 
for Adverse Events, version 3.0. Each patient was classified into one of three categories according to the 
most severe grade (G) of neutropenia experienced throughout treatment: G0, none; G1–2, moderate; G3–4 
or febrile neutropenia, severe. Primary prophylaxis with granulocyte-colony stimulating factors was not 
permitted. 
 
Statistical Methods  
The primary endpoint of this study was the association between neutropenia and overall survival, defined 
as the interval between the date of randomization and the date of death, due to any cause. Patients who 
were lost to follow-up (n = 12) before death were censored at the last contact date. The database was 
locked on November 9th, 2007; at this date, after a median follow-up of 87 mo (range: 68–108 mo), 507 
events (89.9%) had occurred, and 45 patients were still alive. Given the rationale behind this study, the 
subsequent analyses were separately performed in each treatment arm. As preliminary analysis, the overall 
survival functions according to the severity of neutropenia were estimated and compared in the three 
groups of patients defined by the worst neutropenia experienced by each patient during follow-up. Kaplan-
Meier's method and log-rank test were used for estimation and comparison, respectively. This approach 
was used simply for graphical representation but not for drawing conclusive results, since neutropenia was 
not a baseline feature and varied over time (Yamanaka et al., 2007). Therefore, the main analysis consisted 
of using Cox's regression models, including a time-dependent covariate (TDC) defined from the updated 
measurements of the chemotherapy-induced neutropenia. For each patient, the worst grade of 
neutropenia occurring between randomization and time T > 0 was defined as the value of the TDC at T 
(Shitara et al., 2009, 2010b; Yamanaka et al., 2007). The value of the variable for each individual patient, 
therefore, was not decreasing over time and could change over time according to the severity of 
neutropenia occurring by that time. The effect of the TDC on survival was adjusted for the following fixed 
covariates (Kohne et al., 2002; Sanoff et al., 2008): sex, age, PS at inclusion, number of metastatic sites, 
percentage of liver involvement with tumor, dose intensities of 5-FU and l-OHP, prior adjuvant 
chemotherapy, Dukes' stage at diagnosis, site of primary tumor, surgical resection of the primary tumor, 
prior surgery of metastases, baseline circulating leukocyte count, plasma alkaline phosphatase activity, and 
concentrations of carcinoembryonic antigen (CEA) and CA19.9. 
The difference in the effect of worst neutropenia (as TDC) on overall survival between treatment arms was 
further explored by comparing the coefficients of the neutropenia variables obtained in the Cox models for 
each treatment arm. More precisely, the square of the difference between the natural logarithms of the 
hazard ratios (HRs) was divided by the sum of their variances; under the null hypothesis of equality 
between the HRs, the above statistic is asymptotically distributed as a chi-square with 1 degree of freedom. 
Neutropenia incidence and severity per patient was calculated in each treatment arm, and these rates were 
compared with a two-sided chi-square test. Comparisons among the three categories of patients (absent, 
moderate, or severe neutropenia) were performed using nonparametric Mann-Whitney or Jonckheere-
Terpstra tests for continuous measurements and Pearson's chi-square or Fisher's exact two-sided tests for 
proportions of categorical variables. The prognostic value of neutropenia categories on objective response 
rate (WHO criteria) was assessed using a binary logistic regression model. Univariate Cox modeling was 
used to assess the effect of worst neutropenia experienced (as TDC) on progression-free survival. In order 
to avoid possible selection and lead-time bias due to higher risk of developing neutropenia according to the 
increasing number of cycles of chemotherapy received (Yamanaka et al., 2007), further sensitivity analysis 
was performed with a landmark that restricted neutropenia data for patient categorization to the first eight 
courses (Shitara et al., 2009). This analysis only included patients receiving at least eight treatment courses. 
The worst neutropenia encountered during the initial eight courses of chemotherapy was considered as a 
fixed covariate. Survival time was then computed from the completion of the eighth treatment course. 
Exploratory subgroup analyses were performed according to sex and baseline PS, in each treatment arm 
separately, to test the prognostic value of worst neutropenia (as TDC) on overall survival. Finally, 
associations between randomized treatment and progression-free survival, objective response rate, and 
overall survival were explored in the three categories of most severe neutropenia experienced (absent, 
moderate, or severe), using univariate Cox or binary logistic regressions. The threshold for statistical 
significance was set at p < .05. 




Neutropenia Incidence and Patient Features  
Of the 564 patients randomized, 556 (98.6%) are included in the current analysis (279 in the FOLFOX2 arm 
and 277 in the chronoFLO4 arm). Six of the eight remaining patients did not start allocated treatment, 
whereas two received a single course without any available data on hematological toxicity. Nearly twice as 
many patients experienced neutropenia on FOLFOX2 (n = 168, 60.6%) than chronoFLO4 (n = 91, 32.6%) (p < 
.0001). Moderate (G1–2) or severe (G3–4) neutropenia occurred, respectively, in 119 (42.7%) and 69 
(24.7%) patients on FOLFOX2 and in 91 (32.9%) and 18 (6.5%) patients on chronoFLO4 (p < .0001) (Figure 
2A). The most severe episode of neutropenia occurred over the four initial courses for 20.2% of the 
patients, and over the eight initial ones for 61.6% of the patients. Only 7.4% of the patients displayed worst 
neutropenia after the 12th course (Figure 2B). Except for the very first course, moderate or severe 
neutropenia consistently occurred more frequently in patients on FOLFOX2 than chronoFLO4 (Figure 2B). 
Neutropenia occurred more frequently in females than males, both on FOLFOX2 (77.5% vs. 60.7%, 
respectively; p = .003) and on chronoFLO4 (46.5% vs. 34.4%, respectively; p = .04). Similarly, a trend toward 
a higher incidence of G3–4 neutropenia was found in women as compared to men, both on FOLFOX2 
(30.6% vs. 20.8%; p = .06) and on chronoFLO4 (9.6% vs. 4.3%; p = .08). Irrespective of sex, neutropenia was 




FIGURE 2.  (A) Distribution of patients according to the most severe neutropenia experienced in each 
treatment arm. White boxes: no neutropenia (G0). Gray boxes: moderate neutropenia (G1–2). Black boxes: 
severe neutropenia (G3–4). (B) Treatment cycle corresponding to the occurrence of the first worst 
neutropenia episode, in each treatment arm. Continuous line: FOLFOX2. Dashed line: chronoFLO4. 
 
Actual Dose Intensities  
The dose intensities of l-OHP and 5-FU varied significantly according to neutropenia category in each 
treatment arm (p ≤ .011) (Table 1 and Figure 3). Two-by-two comparisons with a threshold p value of .001 
are tagged in Figure 3. Moderate or severe neutropenia was associated with comparable dose intensities in 
both schedules (Table 1 and Figure 3). Conversely, in neutropenia-free patients, the actual dose intensities 
of l-OHP and 5-FU were lower on chronoFLO4 as compared with FOLFOX2 (p < .0001 and p = .004, 




FIGURE 3.  Boxplots representing the actual dose intensity of oxaliplatin (l-OHP, mg/m2/wk; left panel) and 
5-fluorouracil (5-FU, g/m2/wk; right panel), according to the categories of worst neutropenia, in each 
treatment arm (FOLFOX2, grey boxes; chronoFLO4, white boxes). Boxes: 1st and 3rd quartiles; middle line: 
median; bars: range. Highly statistically significant (p ≤ .001) two-by-two differences are tagged. 
 

























Age (yrs) Median 62 62 64 62 62 62 60 62 
  Range 33–76 32–76 37–75 32–76 24–76 22–76 37–71 22–76 
Sex (%) Female/Male 28/73 44/56 49/51 40/60 36/64 46/54 61/39 41/59 
PS (%) 0/1/2 41/44/16 54/40/7 54/41/6 50/41/9 49/40/11 48/41/11 33/50/17 48/41/12 
# metastatic 
sites (%) 
1/2 / ≥ 3 45/35/20 53/31/16 54/30/16 51/32/17 48/36/17 58/36/6 50/33/17 51/36/13 
% liver tumor 
involvement 




Yes 22 12 19 17 16 22 28 18 
Synchronous 
metastases (%) 
Yes 73 81 64 74 76 73 72 75 
primary tumor 
Site (%) 




Yes 86 87 84 86 89 88 89 89 
Prior surgery: 
metastases (%) 





/L 41 19 26 28 31 11 28 24 
Baseline ALP 
(%) 
≥300 IU/L 34 25 19 27 33 23 22 29 
Baseline CEA 
(%) 
≥10 ng/mL 66 70 62 67 68 57 78 65 
Baseline 
CA19.9 (%) 
≥37 IU/L 50 48 45 48 48 42 44 46 
Cycles: total (%) Median 8 12 11 10 9 11 8 10 
  1st and 3rd 
quartiles 
4–10 9–15 8–12 8–12 4–12 8–13 6–11 6–12 






Median 45.3 38.6 35.9 40.1 40.8 38.8 33.2 39.4 
  1st and 3rd 
quartiles 
39.3–50.6 32.2–44.8 31.6–41.9 33.8–
46.4 
33.3–46.6 32.7–44.0 27.3–38.9 32.5–
44.7 






Median 1.51 1.41 1.25 1.41 1.41 1.36 1.17 1.38 
  1st and 3rd 
quartiles 
1.36–1.69 1.25–1.56 1.11–1.42 1.24–
1.60 
1.22–1.61 1.15–1.51 0.98–1.39 1.19–
1.56 
  Range 0.70–1.82 0.64–1.81 0.60–1.73 0.60–
1.82 




Value 16.5 60.5 56.5 45.2 36.3 58.2 44.4 44.0 
  95% CI 8.2–25.8 52.2–69.8 44.7–69.3 38.7–
51.3 
29.7–42.3 27.2–48.8 20.9–67.1 37.7–
50.3 
Median time to 
progression 
(mo) 
Value 4.5 9.7 9.7 8.5 7.7 9.3 9.2 8.3 





% of patients 55.6 75.6 70.1 67.8 68.3 75.6 82.4 71.5 
 
Patient characteristics in each treatment arm according to the categories of the worst neutropenia 
experienced. 
PS = performance status (WHO scale); WBC = white blood cells; ALP = alkaline phosphatases; 
IU = international units. 
*Excluding leukopenia and neutropenia 
 
 
Prognostic Value of Neutropenia on Objective Response and Progression-Free Survival  
Objective response rate varied significantly according to the severity of the worst neutropenia in each 
treatment arm. Thus, response rate was lowest in the neutropenia-free patients than the neutropenic ones, 
both on FOLFOX2 (p < .0001) and on chronoFLO4 (p = .004) (Table 1). The occurrence of neutropenia on 
FOLFOX2 was significantly associated with longer progression-free survival (Table 1) (p = .034). Conversely, 
an opposite trend was noted for chronoFLO4 (p = .061), with patients experiencing severe neutropenia 
displaying a higher risk of earlier progression than neutropenia-free patients (HR: 1.71; 95% confidence 
interval [CI]: 1.08–2.71; p = .023). 
 
Prognostic Value of Neutropenia on Overall Survival  
Median (95% CI) overall survival was 18.5 (17.0–19.9) mo in the FOLFOX2 arm and 19.3 (18.1–20.6) mo in 
the chronoFLO4 arm. 
Preliminary analysis showed that overall survival functions varied significantly according to neutropenia 
category in the FOLFOX2 arm (p < .0001), but not in the chronoFLO4 arm (p = .36) (Figure 4). Overall 





FIGURE 4.  Overall survival curves in each treatment arm (FOLFOX2, left panel; chronoFLO4, right panel) 
according to the occurrence of the most severe neutropenia. Dotted light gray lines: no neutropenia (G0). 
Dashed darker gray lines: moderate neutropenia (G1–2). Solid black lines: severe neutropenia (G3–4). p 
values derived from log-rank test. This represents the graphical display of preliminary analyses. 
 
TABLE 2.  Cox proportional hazard models for overall survival 
 
 
Cox proportional hazard modeling with neutropenia as the time-dependent covariate (TDC) confirmed that 
the decreased risk of an earlier death conferred by occurrence of neutropenia (moderate or severe) on 
FOLFOX2 remained statistically significant following adjustment for other known prognostic factors (p = .04) 
(Table 2). On the contrary, although the risk of earlier death associated with the occurrence neutropenia 
(as TDC) on chronoFLO4 significantly increased when this toxicity arose (p = .025), multivariate Cox 
proportional hazard modeling found no significant prognostic value for neutropenia on this treatment 
modality, even though a consistently opposite trend to that observed for FOLFOX2 was found (p = .07) 
(Table 2), with patients with severe neutropenia on chronoFLO4 displaying poorest survival. Thus, the 
occurrence of severe neutropenia was independently associated with survival, yet with an opposite relative 
risk of an earlier death, according to treatment modality: a significantly lower risk on FOLFOX2 (HR: 0.56; 
95% CI: 0.35–0.90; p = .015) and a nonsignificant trend toward a higher risk on chronoFLO4 (HR: 1.77; 95% 
CI: 0.98–3.20; p = .06). Indeed, highly significant difference in the effect of the occurrence of neutropenia 
between treatment arms was observed concerning both moderate and severe neutropenia (all p < .001). 
These results remained similar if the worst neutropenia observed for each patient was considered as a 
simple baseline prognostic covariate (not shown). 
Subgroup analyses according to sex or baseline PS confirmed the better prognosis in patients with 
moderate or severe neutropenia on FOLFOX2 in both women and men and in each PS subgroup (p ≤ .18; 
not shown). Conversely, patients with moderate or severe neutropenia on chronoFLO4 tended to display an 
increased risk of earlier death in each subgroup analyzed, although never with statistical significance 
(p ≥ .09; not shown). Thus, the opposite trend of the association between neutropenia and overall survival 
according to the pharmacological schedule found in the whole cohort was recapitulated in every subgroup 
assessed. 
The landmark analysis limited neutropenia data to the first eight courses, and included the 404 patients 
who received at least eight treatment courses (212 patients on FOLFOX2 and 192 patients on chronoFLO4). 
Thus, the relative proportion of patients with moderate or severe neutropenia remained significantly 
higher on FOLFOX2 than chronoFLO4 (p < .0001). Furthermore, the survival of neutropenia-free patients 
was significantly shorter than that of patients with moderate or severe neutropenia on FOLFOX2 (p = .051). 
Conversely, neutropenia-free patients lived longer than the neutropenic ones on chronoFLO4 (p = .002). In 
this landmark group as well, the interaction between the randomized treatment schedule and worst 
neutropenia grade significantly influenced overall survival (p = .005); this association persisted 
independently from the other prognostic factors in a multivariate analysis (p = .001). Further exploratory 
analyses showed that the chances of obtaining a better outcome, i.e., higher objective response rate, 
longer progression-free survival, and longer survival, were significantly increased in neutropenia-free 
patients receiving chronoFLO4 and in severely neutropenic patients treated with FOLFOX2 (Figure 5). 
 
 
FIGURE 5.  Forrest plot of the effect of treatment in each subgroup of patients defined by the most severe 




This international study confirmed, in an independent cohort of patients, that the occurrence of 
chemotherapy-induced neutropenia is associated with improved survival. This was here the case for 
patients receiving conventional FOLFOX for previously untreated metastatic colorectal cancer (Shitara et 
al., 2009). The clinical trial design involved higher than usual starting doses and intrapatient dose escalation 
so as to administer the maximum tolerated dose in each individual patient (Colucci et al., 2005; 
Cunningham et al., 2009; de Gramont et al., 2000; Giacchetti et al., 2006, 2000; Maindrault-Goebel et al., 
2001). The timing of drug administration was not stipulated and varied both among patients and between 
courses for FOLFOX2 (Giacchetti et al., 2006; Innominato et al., 2010; Lévi et al., 2010). Conversely, 
chronoFLO4 delivered the three same drugs at defined times so as to take into account the circadian timing 
system (Giacchetti, 2002; Hrushesky & Bjarnason, 1993; Innominato et al., 2010; Lévi, 2002; Lévi & Schibler, 
2007; Lévi et al., 2007b, 2010). This approach was based on data showing that predictable 24-h changes 
characterize the detoxification of anticancer drugs, as well as tissue-specific replication rates, especially in 
human bone marrow (Abrahamsen et al., 1997; Bjarnason & Jordan, 2002; Bjarnason et al., 1999, 2001; 
Buchi et al., 1991; Harris et al., 1990; Lévi & Schibler, 2007; Lévi et al., 2010; Smaaland et al., 1991, 1992a, 
2002). 
Circadian rhythms in therapeutic effects are generated by molecular clocks residing within each cell and 
coordinated by a hypothalamic pacemaker (Dibner et al., 2010; Lévi & Schibler, 2007; Lévi et al., 2010; 
Paschos et al., 2010). Wrongly timed or excessively dosed cancer medications, in turn, profoundly disrupt 
circadian physiology and molecular clocks in experimental models (Lévi et al., 2010). This results in severe 
alterations of the circadian coordination of both drug-detoxification pathways and cell-cycle gating. This 
circadian disruption interferes with the beneficial control exerted by the circadian timing system on tumor 
progression, and can concurrently hamper both treatment tolerability and anticancer efficacy (Filipski et al., 
2002, 2004, 2005; Lévi et al., 2010). Indeed, robust circadian host physiology predicted for prolonged 
survival, independently of other known prognostic factors in patients with breast or colorectal metastatic 
cancer (Innominato et al., 2009; Mormont et al., 2000; Sephton et al., 2000). Furthermore, this concept 
contrasts chronotherapeutics with the principle that governs conventional cancer treatments: the larger 
the treatment toxicity, the better the antitumor efficacy (Frei & Canellos, 1980; Shitara et al., 2010a). 
However, 2 studies out of 13 reported no positive association between the occurrence of Grade 3–4 
leukoneutropenia and survival (Kim et al., 2010; Miyoshi et al., 2009; Shitara et al., 2010a). In our and most 
other prior studies, no difference in survival has been found between patients with moderate or severe 
neutropenia receiving non–time-stipulated chemotherapy (Figure 4) (Shitara et al., 2010a). These findings 
suggest that in comparing severe to absent or moderate neutropenia, one could blunt existing survival 
differences, mostly related to the occurrence and not the severity of neutropenia (Figure 4) (Shitara et al., 
2010a). The current study provides the first clinical evidence of a substantial difference between non–time-
stipulated and circadian-based chemotherapy for the toxicity-efficacy relationship; despite the same drug 
doses and course frequency being used, the overall observed outcomes were comparable (Giacchetti et al., 
2006). Neutropenic patients on FOLFOX2 displayed best efficacy outcomes independently of other known 
prognostic factors, in accordance with prior reports (Shitara et al., 2009, 2010a; Yamanaka et al., 2007). 
Conversely, the occurrence of neutropenia with chronoFLO4 was not associated with any improvement in 
survival, and was even associated with impaired efficacy outcomes. Despite the low incidence of Grade 3 or 
4 hematologic toxicity on chronoFLO4 (6.5%; Figure 2, Table 1), the negative trend that characterized the 
relationship between neutropenia and survival was almost statistically significant (p = .07; Table 2). 
Moreover, the earlier the occurrence of neutropenia on chronoFLO4, the poorer the survival on this 
schedule, according to the sensitivity analyses in the landmark group (p = .002). The present report 
indicates that wrongly timed and/or excessively dosed chronomodulated treatments could simultaneously 
produce undue toxicity and achieve poor efficacy, in good agreement with experimental data (Lévi et al., 
2010). Thus, the opposite relationships between hematologic toxicity and efficacy outcomes according to 
chronomodulated or conventional drug delivery likely explain the observed similar overall survival of 
patients on either schedule (Giacchetti et al., 2006). Indeed, a specific feature of this trial was that 
chemotherapy doses were escalated from one course to the next until reaching the maximum tolerated 
dose for each individual patient (Giacchetti et al., 2006). The occurrence of neutropenia resulted in 
comparable reductions in the actual dose intensities of l-OHP and 5-FU in both treatment schedules (Figure 
3, Table 1). However, drug doses were reduced also in case of severe clinical toxicities that were slightly 
more frequent in patients on chronoFLO4 (Table 1). No relationship was found between any efficacy 
endpoint and diarrhea on either delivery schedule, even though this symptom was the main dose-limiting 
toxicity on chronoFLO4 (Giacchetti et al., 2006) (data not shown). This finding suggests that bone marrow 
toxicity could induce a peculiar effect on the circadian timing system, possibly through the release of 
proinflammatory cytokines with circadian disruptive effects. Thus, elevated serum levels of transforming 
growth factor-α (TGF-α), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) were associated with 
circadian disruption and poor survival in patients with metastatic colorectal cancer (Rich et al., 2005). 
Altogether, female patients were more likely than men to experience neutropenia (Table 1), in agreement 
with prior reports (Chansky et al., 2005; Diasio & Lu, 1994; Schwab et al., 2008). Each patient on 
chronoFLO4 received the same chronomodulated schedule with respective peak times of l-OHP and 5-FU-
LV delivery rates at 16:00 h and at 04:00 h, selected according to preclinical data from male mice, human 
tissue proliferation studies, and early clinical trials (Abrahamsen et al., 1997; Bjarnason & Jordan, 2002; 
Bjarnason et al., 1999, 2001; Buchi et al., 1991; Giacchetti, 2002; Giacchetti et al., 2006; Lévi et al., 2010; 
Smaaland et al., 1991, 1992a, 2002). A phase I–II clinical trial confirmed the better tolerability of the current 
chronoFLO4 in male patients, through exploring schedules with peak times of drug delivery staggered by 
±3, ±6, ±9, or ±12 h in separate cohorts of patients with metastatic colorectal cancer (Lévi et al., 2007b). In 
female patients, however, a large interpatient variability in optimal timing was apparent, with an ∼6-h 





In conclusion, we confirm here the principle that is currently advocated to guide non–circadian-based 
chemotherapy, i.e., lack of any neutropenia reflects insufficient drug dosing and, therefore, impaired 
efficacy. We show, however, that this principle does not apply to circadian-based delivery. Furthermore, 
severe neutropenia appears to be detrimental to the efficacy of chronomodulated chemotherapy. These 
results support the policy of dose escalation until maximum tolerated dose is reached in each patient for 
non–circadian-based chemotherapy (Frei & Canellos, 1980). Conversely, chronomodulated chemotherapy 
provides a novel treatment paradigm, where good tolerability is required for achieving optimal efficacy 
(Bross et al., 1966). Cancer chronotherapeutics has thus entered a new era: the current main goal consists 
of the joint improvement of both the safety and efficacy of any chemotherapy regimen, through the 
adjustment of drug doses and circadian delivery patterns according to sex and other individual patient 
characteristics. Obviously, this novel strategy of chronopharmacological refinement and personalization 
requires prospective clinical validation. 
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